Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide

• Main Authors: CHRISTOPHER D. V BLACK, ERIC S. GROVES, ASKIS K SAHA, ROBERT A. SNOW, ARUP SEN, CLYDE W SHEARMAN
• Format: Patent
• Language: English
• Published: 22.06.1994
• Edition: 5
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; SUGARS; TESTING; VINEGAR; WINE

The present invention is directed to a non-radioactive targeting immunoreagent that comprises oligonucleotides comprised of non-self-associating oligonucleotide sequences, and one or more linking groups and a radioactive targeting immunoreagent that comprises an oligonucleotide comprised of an oligonucleotide sequence that is complementary in sequence to and capable of hybridization with one or more fragments of a non-self-associating oligonucleotide sequence, one or more chelating agents, one or more linking groups and one or more radionuclides. The present invention is also directed to pharmaceutical compositions comprising one or more of the above-described immunoreagents and a pharmaceutically acceptable carrier. The present invention is further directed to methods for treating and imaging disease sites in patients.